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METHODS: Data for the cost-effectiveness analyses were
obtained from a case control study and two randomized
controlled trials comparing the surgical outcomes related
to temperature control using the Arctic Sun versus the
current surgical warming methods. The incremental cost-
effectiveness per hypothermia case avoided was calcu-
lated by measuring the extra costs to the hospital for
achieving an extra unit of effectiveness by using the Arctic
Sun.
RESULTS: Using the deﬁnition of hypothermia as a 
temperature less than 36°C, there were three cases (5%)
of post-operative hypothermia out of 58 for patients
warmed using the Arctic Sun method. Using the standard
of care, 23 out of 48 patients (48%) were hypothermic.
The treatment costs for preventing post-operative
hypothermia includes $60 in variable costs for the stan-
dard of care. Costs for using the Arctic Sun for prevent-
ing post-operative hypothermia included $350 in variable
costs and $9.85 in allocated annual ﬁxed costs (total
treatment cost—$359.85 per patient). Subtracting the rel-
ative cost to treat 100 patients using the standard of care
($6,000) from the relative cost of warming 100 patients
using the Arctic Sun ($35,985) yielded an incremental
cost effectiveness of $697.33 per post-operative hypother-
mia case avoided by using the Arctic Sun. 
CONCLUSION: Use of the Arctic SunTM is both effective
and cost-effective in preventing post-operative hypother-
mia during OPCAB procedures.
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Approximately 1.5 million individuals experience a
myocardial infarction (MI) each year in the United States.
Of these, 20% develop major depression (MDD) and are
at increased risk of re-infarction, overall morbidity and
mortality.
OBJECTIVE: The objective of this study was to compare
the health care costs and resource utilization for patients
diagnosed with MI + MDD with patients with MI only,
MDD only and a control group having neither condition. 
METHODS: Claims data for all patients at least 40 years
of age from a large HMO in the Southeast US were ana-
lyzed retrospectively. Patients were selected for study if
they had an incident event of MI, MDD, or MI+MDD
during a one-year recruitment period. Age and sex
matched patients having neither MI nor MDD during the
recruitment period served as the control group. Patients
were followed for two years from their dates of recruit-
ment. Patients were included in the MI+MDD group only
if they had at least six months of data for analysis. Only
patients with drug charges were included for ﬁnal 
evaluation.
RESULTS: Compared with $6,877 for patients in the
control group (n = 436), mean total costs were statisti-
cally different for each group, including $13,982 for
MDD patients (n = 296), $35,589 for MI patients (n =
98), and $57,835 for MI+MDD patients (n = 53). Signif-
icant differences between the groups were found for the
number of hospitalizations, length of hospital stay, out-
patient visits, types of prescribed medication, and number
of ﬁlled prescriptions. Other signiﬁcant differences be-
tween groups included their need for therapeutic drug
assays, particularly digoxin, and cardiovascular labora-
tory procedures, particularly the use of devices to monitor
for arrhythmia. 
CONCLUSION: The cost of illness and resource utiliza-
tion for patients who had MI+MDD are much greater
than patients having MI or MDD alone. Early recogni-
tion of patients with MI+MDD is warranted.
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Validity and clinical relevance of the quality of life (QL)
measures developed in Western civilization societies may
quite differ from those in countries experiencing socioe-
conomic hardships.
OBJECTIVES: We aimed to validate the set of QL ques-
tionnaires in essential hypertensives (EH) from Belarusian
population. 
METHODS: Internationally recognized, self-
administered, culturally non-speciﬁc, and professionally
translated into Russian questionnaires were used: the
General Well-Being Adjustment Scale (GWBAS), Duke
Health Proﬁle (DHP), Giessen Somatic Complaints Ques-
tionnaire (GSCQ). The QL assessment was carried out in
212 EH without concomitant diseases (100 males; mean
age 48.5 ± 12.3 years; BMI 30.3 ± 13.3kg/m2; SBP 168.4
± 26.6mmHg, DBP 105.4 ± 13.3mmHg) and in 57 
age-, gender- and BMI-matched healthy subjects.
RESULTS: Cronbach’s coefﬁcient alpha more then 0.7
was determined for GWBAS subscales (range 0.67–0.84;
mean 0.77) excepting “self-control”, for GSCQ (range
0.54–0.86; mean 0.74) excepting “gastric complains”,
but not for DHP (range 0.47–0.68; mean 0.57). Correla-
tion matrix revealed signiﬁcant and the highest Spearmen
correlation coefﬁcients of GWBAS subscales scores with
corresponding DHP and GSCQ subscales scores, except-
ing GWBAS subscale “vitality”. The total well-being
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index of GWBAS in EH was lower (80.0 ± 16.9 vs. 90.3
± 15.3 points; p < 0.0001) and the total complaints index
of GSCQ was higher (29.7 ± 17.4 vs. 15.9 ± 9.7 points;
p < 0.000001) compared with the healthy control.
CONCLUSIONS: Some discrepancies were revealed in
testing results of the studied QL measures in developed
and transitional societies. GWBAS and GSCQ demon-
strate sufﬁcient internal consistency reliability, convergent
and discriminate validity, as well as sensitivity and may be
used for the QL assessment in EH living in an unstable
economy. DHP seems to be less reliable, probably due to
brevity and intersected structure of subscales, and should
be applicable mainly for fast preliminary QL screening.
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OBJECTIVE: The Joint National Committee (JNC) 
on Detection, Evaluation, and Treatment of High Blood
Pressure V (1993) and VI (1997) recommended diuretics
and beta-blockers as initial antihypertensive drugs.
However, a few studies have shown a trend of the increas-
ing use of angiotensin-converting enzyme inhibitors
(ACEIs) and calcium channel blockers (CCBs), and the
decreasing use of diuretics and beta-blockers. Hyperten-
sion is one of the most common reasons for patients to
use clinic visits. The purpose of the study was to assess
the association between the different patterns of antihy-
pertensive drug use and the number of clinic visits for
essential hypertension.
METHOD: Poisson regression model was employed to
assess the association between the different patterns of
antihypertensive drug use and the number of clinic visits
by using the Medical Expenditure Panel Survey (MEPS,
1996), after controlling for confounding variables. The
study population enrolled was estimated 10,357,769
non-institutionalized adult US patients with essential
hypertension.
RESULTS: Patients with diuretics or beta-blockers had
fewer clinic visits, compared to patients with ACEIs or
CCBs (p < 0.01). Patients in good physical health had
fewer clinic visits, compared with patients in fair or poor
physical health (p < 0.05). Other signiﬁcant explanatory
variables include census region and limitations in daily
life activities. 
CONCLUSION: Patients using ACEIs or CCBs, which
were not recommended by the current JNC guidelines had
more clinic visits. This association needs to be concerned
in the management of hypertension.
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OBJECTIVE: To estimate the UK population of people
with type 2 diabetes who would be eligible for treatment
with ramipril for secondary prevention of cardiovascular
events, as deﬁned by the inclusion criteria of the MICRO
HOPE trial, as a basis for estimating the NHS budget
impact of treatment. 
METHOD: Patients were eligible to participate in the
MICRO HOPE trial if they were over 55 years of age
with diabetes and one other risk factor for cardio-
vascular disease (total cholesterol >5.2mmol/L, HDL 
cholesterol £0.9mmol/L, hypertension, known microal-
buminuria, or current smoking). Exclusion criteria
included dipstick positive proteinuria and present usage
of ACE inhibitors. We used published national prevalence
data to identify the number of people with Type 2 dia-
betes over 55 in the UK at present. In order to estimate
the percentage of these patients who would ﬁt the
MICRO HOPE inclusion criteria, we conducted a review
of the South Teeside Diabetes Register.
RESULTS: There were 6998 people with diabetes on the
South Teeside District Diabetes Register in 2000. 4,733
were over 55 years of age, and of these patients 2,777
had available data for proteinuria: 496 (18%) patient
tested positive, 2,281 (82%) were negative. 1,010 (36%)
patients had additional risk factors as well as being 
proteinuria negative and not being treated with an ACE
inhibitor. There are 816,000 people with Type 2 diabetes
who are over 55 years of age in the UK at present. We
estimate that 294,000 of these patients are eligible for
treatment with ramipril, as prescribed in the MICRO
HOPE trial, but are not presently being treated. For an
average Primary Care Trust with a population of 100,000
people, there are likely to be 493 patients eligible for
treatment. 
CONCLUSION: This estimate gives a measure of 
potential workload for NHS primary care prescribers,
and could populate a budget impact analysis study on 
the cost of implementing the MICRO HOPE trial 
recommendations.
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